(Q36840374)

16 August 2017

1 reference

title

Measuring and management of anti-interferon beta antibodies in subjects with multiple sclerosis (English)

1 reference

16 August 2017

0 references

Rachel A Farrell

1

1 reference

16 August 2017

Gavin Giovannoni

series ordinal

2

1 reference

16 August 2017

publication date

16 February 2007

1 reference

Multiple Sclerosis Journal

16 August 2017

published in

1 reference

16 August 2017

volume

13

1 reference

16 August 2017

issue

5

1 reference

16 August 2017

page(s)

567-577

1 reference

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1352458506073522

PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458506073522

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458506073522

Strategies to treat and prevent the development of neutralizing anti-interferon-β antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458506073522

Persistent neutralizing antibodies abolish the interferon beta bioavailability in MS patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458506073522

The clinical impact of interferon beta antibodies in relapsing-remitting MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458506073522

Biologic impact of interferon antibodies, and complexities in assessing their clinical significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458506073522

Neutralizing antibodies reduce MxA protein induction in interferon-beta-1a-treated MS patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458506073522

Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458506073522

Antibodies to interferon (IFN) in hepatitis C patients relapsing while continuing recombinant IFN-alpha2 therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458506073522

Interferons as biochemical modulators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458506073522

A multicenter, open-label, phase II study of the immunogenicity and safety of a new prefilled syringe (liquid) formulation of Avonex in patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458506073522

Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458506073522

Clinical link between MHC class II haplotype and interferon-beta (IFN-beta) immunogenicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458506073522

Neutralizing antibodies reduce the efficacy of betaIFN during treatment of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458506073522

Serum IFN neutralizing antibodies and neopterin levels in a cross-section of MS patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458506073522

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458506073522

Biological markers of interferon-beta therapy: comparison among interferon-stimulated genes MxA, TRAIL and XAF-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458506073522

Biological responsiveness to first injections of interferon-beta in patients with multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458506073522

Measurement of MxA mRNA or protein as a biomarker of IFNbeta bioactivity: detection of antibody-mediated decreased bioactivity (ADB).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458506073522

Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458506073522

Fate of neutralizing and binding antibodies to IFN beta in MS patients treated with IFN beta for 6 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458506073522

Interferon-beta: the neutralizing antibody (NAb) titre predicts reversion to NAb negativity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458506073522

Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458506073522

Appearance and disappearance of neutralizing antibodies during interferon-beta therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458506073522

Monthly corticosteroids decrease neutralizing antibodies to IFNbeta1 b: a randomized trial in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458506073522

Corticosteroids treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458506073522

Combination of cyclophosphamide and interferon-beta halts progression in patients with rapidly transitional multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458506073522

Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458506073522

The importance of measuring IFNbeta bioactivity: monitoring in MS patients and the effect of anti-IFNbeta antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458506073522

Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458506073522

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458506073522

A comparative study of the relative bioavailability of different interferon beta preparations

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458506073522

Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458506073522

A novel and rapid assay for the detection of neutralizing antibodies against interferon-beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458506073522

21 January 2018

Identifiers

DOI

10.1177/1352458506073522

1 reference

16 August 2017

1 reference